Device Trial Radar · NCT06710873
Analysis of Clinical Application of China's First Batch of TYRX Absorbable Antibacterial Envelope
Last checked: Nov 19, 2026Latest source record: Mar 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
50
Actual
Start
Dec 1, 2023
Primary completion
Oct 9, 2024
Study completion Mar 1, 2026
Sponsor
- Lead sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 29, 2024
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
Summary
As written by the sponsor on the registry.
This study is the first to use TYRX domesticly, reporting and summarizing its usage to validate its real-world effectiveness in CIED infection prevention.
Conditions
- CIED Infection
- TYRX Absorbable Antibacterial Envelope
Interventions
TYRX Absorbable Antibacterial EnvelopeDevice
All enrolled patients will receive the TYRX Absorbable Antibacterial Envelope implanted simultaneously during the CIED surgery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- CIED infectionTime frame: three months post-surgery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun-Yatsen Memorial Hospital of Sun-Yatsen University
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.